Surbhi Sidana
0000-0003-3288-7614
Stanford Medicine
20 papers found
Refreshing results…
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
Reply to R. Chakraborty et al
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma
IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis
Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma
Outcomes with different administration schedules of Bortezomib in Bortezomib, Lenalidomide and dexamethasone ( VRd ) as first‐line therapy in Multiple Myeloma
Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis
Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis
Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis
Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis
Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)
Missing publications? Search for publications with a matching author name.